Advance market commitments: A Policy to stimulate investment in vaccines for neglected diseases

Economists' Voice

Volumn 3, Issue 3, 2006, Pages 1-6

  Barder, Owen ^a,b   Kremer, Michael ^a,c,d   Williams, Heidi ^c  

^a CENTER FOR GLOBAL DEVELOPMENT   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c HARVARD UNIVERSITY   (United States)

^d BROOKINGS INSTITUTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33845491447     PISSN: 15533832     EISSN: 15533832     Source Type: Journal    
DOI: 10.2202/1553-3832.1144     Document Type: Article

References (15)

1. Acemoglu, Daron and Joshua Linn, "Market size in Innovation: Theory and Evidence From the Pharmaceutical Industry," Quarterly Journal of Economics, Vol. 119, No. 3, pp. 1049-1090, 2004.
2. Barder, Owen, Michael Kremer, Ruth Levine, and the Advanced Market Commitment Working Group, Making Markets for Vaccines, Center for Global Development, 2005.
3. Berndt, Ernst, Rachel Glennerster, Michael Kremer, Jean Lee, Ruth Levine, Georg Weisäcker and Heidi Williams, "Advance Purchase Commitments for a Malaria Vaccine: Estimating Costs and Effectiveness," National Bureau of Economic Research (NBER) working paper #11288, 2005.
4. Berndt, Ernst and John Hurvitz, "Vaccine Advance-Purchase Agreements for Low-Income Countries: Practical Issues," Health Affairs, Vol. 24, No. 3, pp. 653-665, 2005.
5. Creese, Andrew, Katherine Floyd, Anita Alban, and Lorna Guinness, "Cost-effectiveness of HIV/AIDS Interventions in Africa: A Systematic Review of the Evidence," Lancet, Vol. 359, pp. 1635-42, 2002.
6. Global Alliance for Vaccines and Immunization (GAVI), "Health, Immunization, and Economic Growth, Research Briefing #2, Vaccines are Cost-effective: A Summary of Recent Research," 2004.
7. Kim-Farley, Robert and the Expanded Programme on Immunization Team, "Global Immunization," Annual Review of Public Health, Vol. 13, pp. 223-237, 1992.
8. Kremer, Michael and Rachel Glennerster, Strong Medicine: Creating Incentives for Pharmaceutical Research on Neglected Diseases, Princeton University Press, 2004.
9. Levine, Orin, Thomas Cherian, Raj Shah, and Amie Batson, "PneumoADIP: An example of Translational Research to Accelerate Pneumococcal Vaccination in Developing Countries," Journal of Health, Population, and Nutrition, Vol. 22, No. 3, pr. 268-274, 2004.
10. Neumann, Peter, Eileen Sandberg, Chaim Bell, Patricia Stone, and Richard Chapman, "Are Pharmaceuticals Cost-Effective? A Review of the Evidence," Health Affairs, Vol. 19, No. 2, pp. 92-109, 2000.
11. Pécoul, Bernard, Pierre Chirac, Patrice Trouiller, and Jacques Pinel, "Access to Essential Drugs in Poor Countries: A Lost Battle?" Journal of the American Medical Association, Vol. 281, No. 4, pp. 361-367, 1999.
12. Phillips, Michael, "Politics & Economics: G-8 Nations Shape Plan to Fight Disease; Goal Is Getting Drug Makers to Generate Vaccines Against Illnesses in Developing World," Wall Street Journal (Eastern edition), 13 February, p. A8, 2006.
13. Towse, Adrian, "What is NICE's Threshold? An External View," Chapter 2 in Nancy Devlin and Adrian Towse (editors), Cost Effectiveness Thresholds: Economic and Ethical Issues, Kings fund / Office of Health Economics, 2002.
14. World Bank, Investing in Health: The World Development Report 1993, World Bank, 1993a.
15. World Bank, Disease Control Priorities in Developing Countries, Oxford Medical Publications, Oxford University Press for the World Bank, 1993b.